Ocrelizumab
- Generic Name
- Ocrelizumab
- Brand Names
- Ocrevus
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 637334-45-3
- Unique Ingredient Identifier
- A10SJL62JY
- Background
Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-humanized CD20 antibodies such as rituximab, ...
- Indication
用于治疗复发型多发性硬化症（MS）。
- Associated Conditions
- Clinically Isolated Syndrome (CIS), Primary Progressive Multiple Sclerosis (PPMS), Relapsing Multiple Sclerosis (RMS), Relapsing Remitting Multiple Sclerosis (RRMS), Active Secondary Progressive Multiple Sclerosis (SPMS)
- Associated Therapies
- -
Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- University of South Florida
- Target Recruit Count
- 18
- Registration Number
- NCT03562975
- Locations
- 🇺🇸
Carol and Frank Morsani Center for Advanced Healthcare, Tampa, Florida, United States
A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2018-05-14
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 927
- Registration Number
- NCT03523858
- Locations
- 🇺🇸
Cleveland Clinic Mellen Center; U10, Cleveland, Ohio, United States
🇺🇸University of Cincinnati; Department of Neurology, Cincinnati, Ohio, United States
🇺🇸Lone Star Neurology of San Antonio, San Antonio, Texas, United States
Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)
- Conditions
- Interventions
- First Posted Date
- 2018-03-26
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- Haukeland University Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT03477500
- Locations
- 🇳🇱
VUmc, Amsterdam, Netherlands
🇳🇴St. Olav's University Hospital, Trondheim, Norway
🇩🇰Rigshospitalet, Copenhagen, Denmark
Mechanism of Action of Ocrelizumab in Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 30
- Registration Number
- NCT03344094
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)
- First Posted Date
- 2017-03-21
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1239
- Registration Number
- NCT03085810
- Locations
- 🇺🇸
University of California Irvine, Irvine, California, United States
🇵🇱Instytut Psychiatrii i Neurologii II Klinika Neurologiczna, Warszawa, Poland
🇺🇸Cleveland Clinic Lou Ruvo; Center for Brain Research, Las Vegas, Nevada, United States
Ocrelizumab Effects on Physiological and Cognitive Changes in Multiple Sclerosis
- First Posted Date
- 2017-01-19
- Last Posted Date
- 2022-03-11
- Lead Sponsor
- University at Buffalo
- Target Recruit Count
- 30
- Registration Number
- NCT03025269
- Locations
- 🇺🇸
Jacobs Institute, Buffalo, New York, United States
Safety of Switching From Rituximab to Ocrelizumab in MS Patients
- First Posted Date
- 2016-12-02
- Last Posted Date
- 2021-07-21
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 200
- Registration Number
- NCT02980042
- Locations
- 🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States
Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
- Conditions
- First Posted Date
- 2016-06-21
- Last Posted Date
- 2017-09-07
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT02807285
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Steward St. Elizabeth's Medical Center, Boston, Massachusetts, United States
🇺🇸University Of Texas Health Science Center Houston, Houston, Texas, United States
A Study of Ocrelizumab in Participants With Follicular Non-Hodgkin's Lymphoma (NHL)
- First Posted Date
- 2016-03-30
- Last Posted Date
- 2016-03-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 48
- Registration Number
- NCT02723071
A Study of Ocrelizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA)
- First Posted Date
- 2016-03-25
- Last Posted Date
- 2016-03-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 175
- Registration Number
- NCT02720120
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.